Beacon Biosignals raises $11M; brings Series B financing to over $97M. April 6, 2026 Beacon Biosignals, a Boston, MA-based company leveraging brain data to advance human health, raised an $11m extension to its Series B financing, bringing the funding round to $97m the cumulative funding to over $132m. The upsized round included new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. This financing builds on Beacon's previously announced $86m Series B, led by a syndicate of leading healthcare and technology investors, including Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures and others. The company intends to use the funds to further accelerate its mission to transform brain health through scalable, at-home EEG and advanced analytics, powering the next generation of diagnostics, clinical trials, and precision medicine. Led by Jacob Donoghue, CEO, Beacon Biosignals combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. The platform provides clinicians and biopharma partners with objective measures of brain function that accelerate research, improve diagnostics, and guide new treatments. 06/06/2026

Beacon Biosignals has extended its Series B financing to $97 million, bringing total funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures and Samsung Next. The Boston-based company combines FDA-cleared wearable EEG technology with AI to capture and analyse brain data for neurology, psychiatry and sleep medicine applications. The additional capital will accelerate Beacon's development of at-home EEG and advanced analytics for diagnostics, clinical trials and precision medicine. The original $86 million Series B was led by healthcare and technology investors including Innoviva, GV, S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital and Indicator Ventures. The platform provides clinicians and biopharma partners with objective measures of brain function.

Beacon Biosignals upsizes Series B financing to over $97 million. GlobeNewswire | Beacon Biosignals Today at 3:30am PDT BOSTON, April 06, 2026 (GLOBE NEWSWIRE) - Beacon Biosignals today announced an extension to its Series B financing, bringing the funding round to $97 million and the company's cumulative funding to over $132 million. The upsized round includes new investors JSL Health, Palo Santo VC, Kicker Ventures, and Samsung Next. This financing builds on Beacon's previously announced $86 million Series B, led by a syndicate of leading healthcare and technology investors, including Innoviva, GV (Google Ventures), S32, Catalio Capital Management, General Catalyst, Logos Capital, Casdin Capital, Indicator Ventures and others. The new capital will further accelerate Beacon's mission to transform brain health through scalable, at-home EEG and advanced analytics, powering the next generation of diagnostics, clinical trials, and precision medicine. "This milestone reflects strong momentum behind our vision to make brain health measurable, scalable, and actionable," said Jacob Donoghue, CEO of Beacon Biosignals. "We're grateful for the support of our new and existing investors as we build the future of brain health." "Beacon is uniquely positioned to unlock the potential of brain data at scale," said Daniel Goldberg, Managing Director at Palo Santo. "Their combination of clinical-grade EEG and advanced analytics is enabling a new era of discovery and precision in neuroscience. As novel therapeutics like psychedelics reshape the treatment landscape for psychiatric disease, platforms like Beacon's will be critical for objectively measuring brain-based outcomes and accelerating development." About Beacon Biosignals Beacon Biosignals is unlocking the power of brain data to advance human health. The company combines FDA-cleared wearable EEG technology with advanced AI to capture and analyze real-world neural data, enabling breakthroughs across neurology, psychiatry, and sleep medicine. The Beacon Platform provides clinicians and biopharma partners with objective measures of brain function that accelerate research, improve diagnostics, and guide new treatments. Learn more at www.beacon.bio. Media Contact: Isabella Lazzareschi, Beacon Biosignals [email protected] This is a paid placement. For further inquiries, please contact GlobeNewswire directly.